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Abstract: 
Traditionally, drugs are discovered by testing compounds synthesized in time consuming multi-step processes against a battery of invivo biological screens. 
Promising compounds are then further studied in development, where their pharmacokinetic properties, metabolism and potential toxicity were investigated. Here, 
we present a study on herbal lead compounds and their potential binding affinity to the effectors molecules of major disease like Prostate Cancer. Clinical studies 
demonstrate a positive correlation between the extent of 5-α reductase type 2 (isoform 2) and malignant progression of precancerous lesions in prostate. Therefore, 
identification of effective, well-tolerated 5-α reductase inhibitors represents a rational chemo preventive strategy. This study has investigated the effects of 
naturally occurring nonprotein compounds berberine and monocaffeyltartaric acid that inhibits 5-α reductase type 2. Our results reveal that these compounds use 
less energy to bind to 5-α reductase and inhibit its activity. Their high ligand binding affinity to 5-α reductase introduces the prospect for their use in 
chemopreventive applications. In addition, they are freely available natural compounds that can be safely used to prevent prostate cancer. 
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Background: 
Prostate cancer (PC) is a cancer that occurs in a man's prostate gland, it is one 
of the most common types of cancer in men [1]. PC generally does not present 
any symptoms until it becomes locally advanced or metastatic disease [2]. 
Androgens are essential for the normal development as well as the onset of 
prostate cancer through their interactions with the androgen receptor (AR) [3], 
However, androgen depletion is usually associated with the recurrence of 
prostate cancer, as monitored by rising PSA levels, and this recurrent disease is 
termed ‘‘androgen independence’’ since advanced prostate cancer remains 
dependent on AR function. The androgen receptor also known as NR3C4 
(nuclear receptor subfamily 3, group C, member 4), is most closely related to 
the progesterone receptor, and progestins in higher dosages can block the 
androgen receptor. The main function of the androgen receptor is as a DNA 
binding transcription factor which regulates gene expression; however, it has 
other functions as well. Androgen regulated genes are critical for the 
development and maintenance of the male sexual phenotype. In some cell types 
testosterone interacts directly with androgen receptors while in others 
testosterone is converted by 5-α reductase to dihydrotestosterone, an even more 
potent agonist for androgen receptor activation. Testosterone appears to be the 
primary androgen receptor activating hormone in the Wolffian duct while 
dihydrotestosterone is the main androgenic hormone in the urogenital sinus, 
urogenital tubercle, and hair follicles. Hence testosterone is primarily 
responsible for the development of male primary sexual characteristics while 
dihydrotestosterone is responsible for secondary male characteristics [2]. 
 
5-α reductase is an enzyme that was first discovered in the male prostate. It 
catalyzes the conversion of testosterone to dihydrotestosterone, which in turn 
binds to the androgen receptor and initiates development of the external 
genitalia and prostate. The gene for 5-α reductase has been mapped to 
chromosome 5 [4]. The isozyme 5-α reductase 2 is transiently expressed in skin 
and scalp of newborns. Type 2 is the predominant isozyme detectable in fetal 
genital skin, male accessory sex glands, and in the prostate, including benign 
prostatic hyperplasia and prostate Aden carcinoma tissues. 5-α reductase 2 
(5αR2) is considered predominant in human accessory sex tissue and is 
responsible for prostate and male external genitalia development [5]. Prostate 
cancer continues to represent a major cause of cancer related mortality and 
morbidity, despite the much recent research progress in the field of prostate 
cancer. Since the early studies of 5-α reductases that lead to the advent of 
androgen deprivation therapy in the 1940s, [3] there has been great interest in 
knowing basic mechanisms underlying prostate cancer initiation and 
progression, as well as the potential to target these processes for therapeutic 
intervention. Here, we present a study on herbal compounds and their potential 
binding affinity to the receptor molecule 5-α reductase.  
 
Methodology: 
Computer aided screening: Two dimensional (2D) similarity searches: 
On the basis of chemical similarity, 2D search with natural inhibitor 
testosterone was performed to find new inhibitors. The presence or absence of BIOINFORMATION  open access 
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common functional groups such as alcohols or ring systems such as 
pyrimidines was investigated [6]. These 5-α reductase inhibitors were selected 
from natural products based on their inhibition specificity, drug application and 
quality. In further steps each compound was analyzed for its possible 
application as a drug. First, we investigated the absorption and permeability 
using the Lipinski's rule of five, which implies that molecules should contain 
less than 10 H-bond-acceptors and less than 5 H-bond-donors. The calculated 
logP value (describes the lipophilic properties) should be less than 5 and the 
molecular weight should be less than 500 g/mol [7]. Any compound violating 
more than one rule was not considered since it is not a promising candidate for 
a drug. 
 
Homology modeling for 3D structure of 5-α reductase-2:  
The PDB structures of drug targets were not available. So, modeling of the 
target proteins were performed using MODELLER. A template search has been 
performed  through BLAST and PSI-BLAST programs [8]. Global alignment 
method was used for comparison between the target-template sequences [9]. 
Gaps with variable gap penalty function are included for structural loops and 
core regions, in order to get maximum correspondence between the sequences. 
Alignment file for MODELLER was prepared by CLUSTALW [10]. Fold 
recognition was done through mGenThreader, and LOMETS server for fold 
assignment  [11]. Energy minimization of generated 3D-model was done 
through GROMACS (OPLS force field) by using Steepest Descent and 
Conjugate Gradient Algorithms [12]. Parameters like covalent bond distances 
and angles, stereo-chemical validation, atom nomenclature were validated 
using PROCHECK and overall quality factor of non-bonded interactions 
between different atoms types were measured by ERRAT program. RMSD 
(root-mean-square deviation) and RMSF (Root Mean Square Fluctuation) was 
calculated for modeled structures. Functionally important residues (Active-site) 
were identified through comparative result of POCKETFINDER and 
SURFACE RACER 4.0.ADMETox box was used to analyse the ADME 
properties of the candidate molecules. 
 
 
Figure 1: (a) Structure of Finasteride; (b) structure of Berberine; (c) structure 
of Monocaffeyltataric acid; (d) Modelled Structure using Modeller and Cartoon 
showing the Α- helix and Coil 
 
Result and Discussion: 
Around 132 small molecules from different categories such as Alkaloids, 
Flavanoids, Tannins and glycosides were taken as targeting agents that are 
responsible for inhibiting the biological processes, important in causing cancer. 
The investigational drug i.e. Finasteride, which is under clinical trial was used 
as a reference drug in this study [13, 14, 15]. Since 5-α reductase type 2 
pathways were mainly responsible for causing prostate cancer, we considered it 
as our target protein and structure for the same was retrieved through 
Homology modeling. Modeling of 5-α reductase type 2 was a tedious task due 
to very low sequence similarity and coverage. Three dimensional model of the 
drug targets were generated through identified templates along with fold fitting. 
Fold recognization was done through mGenThreader and LOMETS server for 
fold assignment. Helices have dominance over other secondary structure i.e. 
sheet, coil in generated model shown in Figure 1. The generated 3D model of 
target proteins was checked by Ramachandran plot using PROCHECK 
program. Ala (69), Leu (86) were identified as active site residues. Initial 
screening of the molecules was based on Lipinski’s rule of five. The molecules 
which satisfy the criteria were subjected to receptor-ligand interaction study 
using docking tool such as Quantum. Molecules which showed better 
interactions with 5-α reductase type 2 than Finasteride (reference drug) were 
considered and subjected to one more docking tool i.e. Quantum, a commercial 
tool for finding Receptor-ligand interaction and docking score was considered 
for further result interpretation.  
 
Docking, Binding Site Analysis, and Catalytic active site Analysis: 
Protein ligand docking was performed using Quantum 3.3.0 and Hex 4.5. The 
active site of an enzyme contains the catalytic and binding sites. The structure 
and chemical properties of the active site allow the recognition and binding of 
the substrate. The Gbind scores from docking of our chemopreventors were 
compared to our standard drug (finasteride) and screening was done further to 
narrow our search for potent inhibitor of 5-α reductase type 2 (Figure 2b, 2c). 
  
Post Docking Study Analysis: 
The receptor-ligand complex of the molecules was subjected to active site 
analysis using SwissPDBviewer (Version 4.0.1) to find the amino acids 
contributing for binding pocket. The Finasteride, an investigational drug for 5-
α reductase type 2 is interacting with Methionine-222, Leucine-42 and 
Glutamine-224 in terms of hydrogen bond. The Berberine is interacting with 
Leucine-154 and Isoleucine-182 whereas Monocaffeyltartaric acid is 
interacting with Aspargine-144, Methionine-141, and Isoleucine-128. The 
hydrogen bonds of all complexes were located using this tool. Table 1 (see 
Supplementary material) shows the binding site results along with the 
Hydrogen bond distance, IC50 (calculated using Quantum 3.3.0) for Berberine 
and Monocaffeyltartaric acid. The half maximal inhibitory concentration 
(IC50) is a measure of the effectiveness of a compound in inhibiting biological 
or biochemical function. This quantitative measure indicates how much of a 
particular drug or other substance (inhibitor) is needed to inhibit a given 
biological process (or component of a process, i.e. an enzyme, cell, cell 
receptor or microorganism) by half. In other words, it is the half maximal 
(50%) inhibitory concentration (IC) of a substance (50% IC, or IC50) [16]. IC50 
value for standard drug (Finasteride) is calculated to be 3.64e
-001 whereas the 
values for natural compounds: Berberine=9.71e
-001 and Monocaffeyltartaric 
acid = 3.05e
-001    
 
 
Figure 2: (a) Natural inhibitors of 5α reductase typeII; (b) Results of docking 
using Quantum program; (c) Comparison of IC50 of natural compounds with 
standard.  
 
ADME and toxicity analysis: 
Twelve major pharmacokinetics and pharmacodynamics features were 
predicted for molecules which showed good interaction with 5-α reductase type 
2. Moreover, the important features like bioavailability, solubility, drug plasma 
binding protein and volume of distribution was considered for comparison 
studies. Toxic effects of molecules were predicted solely from the chemical 
structure. The ADME and Toxicity properties were predicted using ADME 
Box and TOX Box tool (http://pharmaalgorithms.com/webboxes/). Tox Box 
employs large and validated databases, robust Structure-Activity Relationship 
(QSAR) models in combination with expert knowledge in organic chemistry 
and toxicology. AMES test parameter was used for finding mutagenicity of the 
molecules. Health effects in blood, cardiovascular, gastrointestinal system, 
kidney, liver, and lungs were predicted. Table 1 (see supplementary 
material)  shows the ADME and toxicity properties of molecules and 
Finasteride. It has been found that among all the top twelve small molecules 
showing better docking score lower than Finasteride (reference drug), 
Berberine and Monocaffeyltartaric acid were non-commercially available BIOINFORMATION  open access 
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hence both Berberine and Monocaffeyltartaric acid were considered as a better 
lead compound than our reference drug (Finasteride) (Table 2 see 
Supplementary material). Further, ADME-TOX results predict that the 
Berberine and Monocaffeyltartaric acid natural compounds have lower toxicity 
than the reference drug. The above synthetic Finasteride inhibitors, prevent or 
slow down the growth of cancer by dihydrotestosterone suppression [13], and 
in turn reduce the prostate size [16]. The natural compounds, Berberine and 
monocaffeyltartaric acid (Flavonoid) are found to be the major phenolic 
constituents in flowers, roots, leaves and involucral bracts and also in the 
medicinal preparations tested [17]. Berberine is a quaternary ammonium salt 
from the group of isoquinoline alkaloids, derived from tyrosine L- DOPA. It is 
found in such plants as Berberis, goldenseal (Hydrastis canadensis), and Coptis 
chinensis, usually in the roots, rhizomes, stems, and bark. Berberine prevents 
and supresses proinflammatory cytokines. Berberine is an alkaloid derived 
from tyrosine, L-DOPA. Berberine has drawn extensive attention towards its 
antineoplastic effects. It seems to suppress the growth of a wide variety of 
tumor cells including breast cancer, leukemia, melanoma, epidermoid 
carcinoma, hepatoma, oral carcinoma, tongue carcinoma, glioblastoma, 
prostate carcinoma, gastric carcinoma. Animal studies have shown that 
berberine can suppress chemical-induced carcinogenesis, tumor promotion, 
tumor invasion, prostate cancer, neuroblastoma, and leukemia. It is a radio-
sensitizer of tumor cells but not of normal cells. Berberine seems to act as an 
herbal antidepressant and a neuroprotector against neurodegenerative disorders.   
 
Conclusion: 
Our study further confirms that computer aided drug screening is an effective 
alternative for identification of lead compounds. Several natural lead 
compounds were identified and tested using molecular docking for their 
effectiveness against prostate cancer. Berberine and monocaffeyltartaric acid 
were identified to be effective inhibitors that have the ability to bind to 5-α 
reductase type 2. Their binding energies were also found to be lower than 
finasteride. Our results contribute to understanding the mechanisms to explain 
previous experimental observations and may provide a lead into anticancer 
research.  
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Supplementary material: 
 
Table 1: Entire details of 2 molecules out of 12 screened compounds that follow lipinsky rule 
S.  No  Compound name  Compound source        Docking score  Neighboring amino acid  H-bond interaction  Ic50 
     HEX  QUANTUM       
1 Finasteride(std  drug)    -211.88  -26.84  Met222,glu224,leu42  1.17,1.32,1.91  3.64e-001 
2 Beberine    Oregon  grape  -178.45  -29.58  Leu154,ile54  3.24;5.12  9.71e-001 
3 Monocaffeyltartaric 
acid 
Taraxacum afficinale  -159.57  -31.06  Asn144,met141,ile128  1.08,2.6o,2.64  3.04e-001 
 
Table 2: ADMET properties of the compounds 
S. No  Molecules  ADME properties  Toxicity properties 
    Oral Bioavailability  Solubility  Drug binding to 
plasma protein 
Volume of 
Distribution 
AME
S 
Health effects 
B* C* G* K* Li*  Lu* 
1 Finasteride  %F(Oral)>30%:0.95 
%F(Oral)>70%:0.773 
-4.03 %PPB:89.81% 
logKaHSA:3.71 
1.97  L/Kg  0.001 0.82 0.91 0.65 0.92 0.94 0.98 
2 Berberine  %F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
-6.56 %PPB:25.86% 
logKaHSA3.15 
2.54  L/Kg  0.644 0.50 0.97 0.95 0.99 0.98 0.91 
3 Cichoric  %F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
-3.78 %PPB:87.02% 
logKaHSA4.43 
0.23  L/Kg  0.088 0.87 0.46 0.97 0.29 0.89 0.24 
4 Cyanin  %F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
-3.73 %PPB:88.61% 
logKaHSA4.50 
0.25  L/Kg  0.034 0.99 0.91 0.99 0.55 0.92 0.87 
5 Delphinidi  3-
rutinoside 
%F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
-5.90 %PPB:54.23% 
logKaHSA1.55 
0.82  L/Kg  0.026 0.99 1.00 1.00 0.88 0.98 0.62 
6 Docosahexen
oic acid 
%F(Oral)>30%:0.854
%F(Oral)>70%:0.450 
-4.26 %PPB:99.97% 
logKaHSA6.06 
0.52  L/Kg  0.996 0.97 0.11 0.05 0.84 0.79 0.89 
7 Gallotannin %F(Oral)>30%:0.033
%F(Oral)>70%:0.009 
-2.90 %PPB:99.90% 
logKaHSA3.40 
0.58  L/Kg  0.037 0.95 0.95 0.99 0.95 0.74 0.93 
8 Leucocyanidi
n 
%F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
-3.16 %PPB:62.39% 
logKaHSA2.70 
1.11  L/Kg  0.020 0.74 0.74 0.81 0.76 0.86 0.78 
9 Mono-
caffeyltartaric 
acid 
%F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
-1.41 %PPB:33.76% 
logKaHSA3.38 
0.25  L/Kg  0.071 0.31 0.17 0.34 0.07 0.32 0.29 
10 Phytic  acid  %F(Oral)>30%:0.033
%F(Oral)>70%:0.008 
2.94 %PPB:0.oo9% 
logKaHSA3.71 
0.30L/Kg  0.010 0.26 0.99 0.01 0.84 0.49 0.65 
 